Welcome to Awesome Blog Design perfect blog

Tag: Merck

Business, Healthcare

Merck presents results from head-to-head Phase 3 KEYNOTE-598 Trial evaluating KEYTRUDA® (pembrolizumab) in combination with ipilimumab versus KEYTRUDA Monotherapy in certain patients with metastatic non-small cell lung cancer

Findings Presented in World Conference on Lung Cancer 2020 Presidential Symposium and Published in the Journal of Clinical Oncology KENILWORTH, N.J. — (BUSINESS WIRE) — $MRK #MRK— Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data

Business, Healthcare

Merck announces third-quarter 2020 financial results

Third-Quarter 2020 Worldwide Sales Were $12.6 Billion, an Increase of 1%; Excluding the Impact from Foreign Exchange, Sales Grew 2% KEYTRUDA Sales Grew 21% to $3.7 Billion Animal Health Sales Grew 9% to $1.2 Billion; Excluding the Impact from Foreign Exchange, Sales

Business, Healthcare

LYNPARZA reduced risk of death by 31% vs. Enzalutamide or Abiraterone for men with BRCA1/2 or ATM-mutated metastatic castration resistant prostate cancer who progressed following enzalutamide or abiraterone in Phase 3 PROfound trial

LYNPARZA is the Only PARP Inhibitor to Demonstrate Improved Overall Survival in Metastatic Castration-Resistant Prostate Cancer KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase 3 PROfound

Business, Healthcare

Merck presents promising new data for three investigational medicines from diverse and expansive oncology pipeline at ESMO Virtual Congress 2020

Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor) Merck to Initiate Phase 3 Study of Vibostolimab in Non-Small

Business, Healthcare

Merck’s KEYTRUDA® (pembrolizumab) reduced the risk of distant metastasis or death by 40% versus placebo as adjuvant treatment in resected, high-risk stage III melanoma

Long-Term Findings From EORTC1325/KEYNOTE-054 Show Adjuvant KEYTRUDA Demonstrated a Sustained Recurrence-Free Survival Benefit Versus Placebo Across Stage IIIA (>1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma Merck Is Advancing a Broad Clinical Program Evaluating KEYTRUDA for the Early Treatment of Cancer